Search
From the New York Stock Exchange, AstraZeneca CEO Pascal Soriot shares his take on M&A, oncology, Baxfendy for hypertension, the obesity market, and more
In New York to ring the open bell in celebration of the listing of the AstraZeneca's ordinary shares on the NYSE earlier this year, he discusses M&A, PD-1 x VEGF, PD-1 x TIGIT, Baxfendy, and the company's efforts in obesity ahead of this weekend's American Diabetes Association Scientific Sessions.
Jun 5
.png){kind=logo}